Biogen Inc.
BIIBHIGH VELOCITYFILING INTENSITYBiogen Inc. reads as High Velocity (composite 78/100); pressure / disclosure signals dominate the posture this cycle · primary market Healthcare.
Lens
Disclosed M&A capital (2023–2025)
$8.1B
vs $75M in 2020–2022
Disclosed transactions
3
3/3 active fiscal years in window
Buyer archetype
Platform Builder
Large and recent disclosed spend expands platforms or service-line scale.
Composite score
78
High Velocity dominates · Filing Intensity
Behavioral posture, nine reads.
Each index scores the issuer 0–100 against an EDGAR-anchored definition. Scores ≥ threshold elevate the issuer into the index's constituent set; the dominant index drives the masthead label.
Active Acquirer
Companies actively deploying disclosed capital into M&A
- $9.7B disclosed buyer spend
- Filed within 27d
Buyer Cadence
Buyer-side companies with recent filing activity
- Filed within 27d
- 293 8-Ks
Target Probability
Issuers showing target-side patterns from filings
- Control-process language
- 25 activism filings
Spin/Carve
Issuers showing spin-off, carve-out, or sum-of-parts posture
- 25 activism filings
Pressure Watch
Issuers facing activism, governance, or control pressure
- 25 activism filings
- Latest activism 2.7y ago; discounted
- Control-process filings
Distress Watch
Issuers showing financial-distress filing patterns
- 25 activism filings
Restatement Risk
Issuers with accounting-integrity flags from filings
- 2 NT late filings
- Latest event 20y ago; heavily discounted
Capital Velocity
DominantIssuers with the highest filing-activity intensity
- 293 8-Ks
- Filed within 27d
- 5 form types
Quiet Power
Large issuers with low signal volume and clean disclosure cadence
- Enterprise value $31.7B
- 10-Q 27d ago
- 5 active signals
Capital cadence.
Ten-year disclosed M&A activity. Bars show spend ($MM); ticks show recorded transaction count. Disclosure tier annotated where v6 audited corpus carries an entry.
Disclosed spend $MM Disclosed transactions (right axis)Peak spend year: $6,926M · Peak count: 1
| FY | Disclosed buys | Disclosed spend | Avg ticket | Audited tier |
|---|---|---|---|---|
| 2025 | 1 | $85M | $85M | N/A |
| 2024 | 1 | $1.1B | $1.1B | N/A |
| 2023 | 1 | $6.9B | $6.9B | N/A |
| 2022 | N/A | N/A | N/A | N/A |
| 2021 | N/A | N/A | N/A | N/A |
| 2020 | 1 | $75M | $75M | N/A |
Strategy posture.
The buyer's playbook in terms of strategic archetype: what each disclosed move says about how they're deploying capital.
Archetype mix
- Platform25%
- Technology Acquisition25%
- Talent Acquisition25%
- Geographic Expansion25%
Strategy keywords
Terms recurring across recent 10-K acquisition disclosures.
- technology_acquisition
- platform
- talent_acquisition
- geographic_expansion
- tuck_in
Filing language.
Direct excerpts from acquisition disclosures and strategy sections: the verbs the buyer chose, in the filings they signed.
“Following the completion of our acquisition of 100% of the rights to TYSABRI from Elan in April 2013, we are solely responsible for the marketing and sale of TYSABRI for MS in the U.S. and the rest of world.”
“In addition to obtaining the rights to Raxatrigine and additional product candidates in preclinical development, we retained the services of key employees of Convergence.”
“On April 2, 2013, we acquired full ownership of, and strategic, commercial and decision-making rights to, TYSABRI from Elan.”
“The acquisition was funded from our existing cash on hand and has been accounted for as the acquisition of a business.”
“In December 2021 and May 2022 we announced our plans to implement a series of cost-reduction measures that when completed we expect may yield approximately $1.0 billion in expense savings. These savings are being achieved through a number of initiatives, including reductions to our workforce, the substantial elimination of our commercial ADUHELM infrastructure, the consolidation of certain real estate locations and operating efficiency gains across our selling, general and administrative and research and development functions.”
Market context.
Where this issuer sits inside its SE-Cluster rollup wedge, with disclosed-spend rank plus trading comparables against the public peer set.
Primary market
Healthcare
- Market spend (2023–2025)
- $195B
- Market spend (2020–2022)
- $253.6B
- Recent vs prior
- −23%
- Issuer rank in market
- N/A
- Share of market capital
- 0.0%
Valuation positioning
BIIB trades at a -1.6-turn discount to the Healthcare peer median of 12.9×.
- EV / Revenue
- 3.2×
- Net debt / EBITDA
- 1.0×
- Peer median EV / EBITDA
- 12.9×
Trading comparables
FMP market data · 2026-05-10
| Company | EV / EBITDA | EV / Rev | Net debt / EBITDA | Revenue | M&A 2023–2025 |
|---|---|---|---|---|---|
AbbVie Inc.ABBV | 23.4× | 6.7× | 3.1× | $62.8B | $18B |
| 17.2× | 0.9× | 1.9× | $449.7B | $28.1B | |
Amgen Inc.AMGN | 12.9× | 6.0× | 2.6× | $37.2B | $26.7B |
| 11.7× | 0.5× | 2.5× | $200.4B | $6.4B | |
Biogen Inc.BIIB | 11.4× | 3.2× | 1.0× | $9.9B | $8.1B |
| 9.3× | 1.9× | 2.8× | $76.4B | $1.3B |
Trading multiples from FMP market data; disclosed M&A spend from the SE-Cluster EDGAR 10-K corpus. Peer set = top disclosed buyers in Healthcare. Bars scaled to the highest EV/EBITDA in the set.
Buyer landscape.
Public buyers whose stated archetypes, target categories, and recent cadence align with this issuer as a plausible acquisition target. Scores cross EDGAR signal and disclosure overlap.
Likely buyers
No public buyers surface as a strong target-side fit on current signal.
Likely sellers / divestiture partners
No reciprocal divestiture / strategic-alternatives matches identified.
Filing activity & signal stream.
Filing cadence and event-driven signals visible on EDGAR. The signal stream below is curated from restatement / spin-carve / activism categories, providing context for any near-term call.
Filing cadence
- 10-K (annual)302026-02-06
- 10-Q (quarterly)942026-04-29
- 8-K (event)2932026-04-29
- Proxy / DEF 14A1282026-04-28
- Activism (13D / DFAN / PREC)252023-09-28
Signals on file
- watch
Late-filing notice
2006-08-102 NT 10-K/10-Q filings on file.
- elevated
Activism on file
2023-09-2825 activist filings on file (13D, DFAN14A, PREC14A series).
- info
Signal
Serial acquisition history
- info
Signal
10-K strategy themes
- info
Signal
Recent transaction activity
Audited corpus.
No audited record on file for this CIK in the current v6 corpus.
This issuer has not been extracted into the v6 audited acquirer corpus yet. The brief above pulls from ranking-level aggregates and issuer-index signal only.